The goal of this clinical trial is to gain more information about how FAPI (fibroblast activation protein inhibitor) binds to certain type of cells in the tumor tissue. The main question it aims to answer is how this information can be used to better diagnose and track prostate cancer. Participants will undergo two PET/MRI scans during two research visits, each of which may last up to 2.5 hours.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
30
5 +/- 2 mCi of Ga-FAPI-46
Undergo PET scan
Undergo MRI scan
University of Wisconsin
Madison, Wisconsin, United States
RECRUITINGPerformance of FAPI for lesion detection
Sensitivity and specificity for lesion detection on FAPI will be compared with that of PSMA PET, using a composite reference standard (all available histology, follow up clinical/standard of care imaging, serum PSA).
Time frame: Duration of scan, up to 80 minutes
Lesion FAPI uptake on PET
FAPI uptake as measured by SUV will be correlated against tissue FAP positivity on immunohistochemistry and FAP expression on qPCR, using linear regression.
Time frame: Duration of scan, up to 80 minutes
Total FAPI-positive tumor volume change
The total FAPI-positive tumor volume between pre- and post-treatment exams will be measured and compared to PSMA-response, other standard-of-care imaging response, and overall survival when available, using odds ratios for treatment response and Kaplan-Meier curve for survival.
Time frame: Duration of scan, up to 80 minutes
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.